



Health and Youth Care Inspectorate – Pharmaceutical Affairs

CERTIFICATE NUMBER: *NL/H 18/2001417A*

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}

Part 1

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Netherlands confirms the following:

The manufacturer: *I.D.B. Holland B.V.*

Site address: *Weverstraat 17, BAARLE-NASSAU, 5111PV, Netherlands*

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC transposed in the following national legislation:

Art. 100 of the Medicines Act

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on *2018-01-25* , it is considered that it complies with :

- The principles of GMP for active substances³ referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.



Part 2

Manufacture of active substance. Names of substances subject to inspection :

LUTETIUM (177LU)-CHLORIDE(nl) / LUTETIUM (177LU) CHLORIDE(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES	
Active Substance : LUTETIUM (177LU) CHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates <i>Special Requirements:</i> 5. Radiopharmaceuticals
	3.1.2 Manufacture of crude active substance <i>Special Requirements:</i> 5. Radiopharmaceuticals
3.4	Manufacture of sterile Active Substance
	3.4.2 Terminally sterilised <i>Special Requirements:</i> 5. Radiopharmaceuticals
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) <i>Special Requirements:</i> 5. Radiopharmaceuticals
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) <i>Special Requirements:</i> 5. Radiopharmaceuticals
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing <i>Special Requirements:</i> 5. Radiopharmaceuticals
	3.6.3 Microbiological testing including sterility testing <i>Special Requirements:</i> 5. Radiopharmaceuticals
	3.6.4 Biological Testing <i>Special Requirements:</i> 5. Radiopharmaceuticals

4. Other Activities - Active Substances :

Category 3.6.3. Parametric release/ Category 3.6.4 is endotoxine testing only



Clarifying remarks (for public users)

Registrationnumber 6952 API

2018-01-26

Name and signature of the authorised person of the
Competent Authority of Netherlands

Drs Yolanda van Kooij
Health and Youth Care Inspectorate – Pharmaceutical
Affairs

Tel: +31 88 1205000

Fax: +31 88 1205001